Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciproflaxacin. Albino rabbits received intrastromal injections of 5 x 102 aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an averaged of 3.1 x 107 organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in treatment of aminoglycoside-resistant P aeruginosa keratitis.
|Original language||English (US)|
|Number of pages||3|
|Journal||Archives of ophthalmology|
|State||Published - Oct 1988|
ASJC Scopus subject areas